JAK Janus Kinase
| Zeile 22: | Zeile 22: | ||
'''Fedratinib''' | '''Fedratinib''' | ||
{{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}} | {{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}} | ||
| + | |||
| + | '''Ruxolitinib''' | ||
| + | {{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}} | ||
| + | {{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}} | ||
| + | {{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}} | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
'''Methotrexate mtx''' | '''Methotrexate mtx''' | ||
{{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}} | {{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}} | ||
Version vom 28. Juni 2020, 11:30 Uhr
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
| 32535597 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. |
32385052 2020. ...The potential role of JAK inhibitors in the management of COVID-19.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Tofacitinib
32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
Baricitinib
32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
32333918 ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
32032529 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
32473600 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
32251638 2020. Baricitinib for COVID-19: a suitable treatment?
32251639 2020. Baricitinib for COVID-19: a suitable treatment? - Authors reply
32437019 2020. Baricitinib: A chance to treat COVID-19?
Fedratinib
| 32205092 ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |
Ruxolitinib
32450201 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
32470486 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
32405693 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Methotrexate mtx
32454489 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
